Analyst Ratings for Innate Pharma S.A. (IPHA)

IPHA Rating Summary

IPHA Price Target Summary

* Over Last 12-Mos
  |   Expand Research on IPHA
Overall Rating: BUY   Rating Trend: Down   Avg. $ Target: $5.75 (+226.7%) * Over Last 12-Mos
Rating Score: 8 / 10   Percentile Rank: 83%
Date Firm Analyst Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
3/11/2026 BTIG Jeet Mukherjee New Coverage Buy
(N/A)
8.00
(N/A)
1.64
(1.76)
7.32% Details
10/29/2025 H.C. Wainwright Swayampakula Ramakanth Upgrade Buy
(Neutral)
5.00
(N/A)
2.09
(1.76)
-15.79% Details